AVDL Avadel Pharmaceuticals Plc

Price (delayed)

$2.32

Market cap

$136.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.54

Enterprise value

$221.22M

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime ...

Highlights
The revenue has plunged by 100% YoY
The gross profit has shrunk by 100% YoY

Key stats

What are the main financial stats of AVDL
Market
Shares outstanding
59.04M
Market cap
$136.97M
Enterprise value
$221.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$97.81M
EBITDA
-$96.95M
Free cash flow
-$87.94M
Per share
EPS
-$1.54
Free cash flow per share
-$1.5
Book value per share
$0.94
Revenue per share
$0
TBVPS
$3.47
Balance sheet
Total assets
$221.13M
Total liabilities
$165.9M
Debt
$145.13M
Equity
$55.23M
Working capital
$116.72M
Liquidity
Debt to equity
2.63
Current ratio
3.65
Quick ratio
2.8
Net debt/EBITDA
-0.87
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-35.6%
Return on equity
-102.8%
Return on invested capital
-32.9%
Return on capital employed
-55.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVDL stock price

How has the Avadel Pharmaceuticals stock price performed over time
Intraday
-4.53%
1 week
-0.85%
1 month
-36.96%
1 year
-68.26%
YTD
-71.29%
QTD
-66.03%

Financial performance

How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$99.36M
Net income
-$90.31M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% YoY
The gross profit has shrunk by 100% YoY
Avadel Pharmaceuticals's net income has decreased by 17% from the previous quarter
The company's operating income fell by 16% QoQ

Growth

What is Avadel Pharmaceuticals's growth rate over time

Valuation

What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Avadel Pharmaceuticals's EPS has decreased by 17% QoQ
The company's equity has shrunk by 60% YoY and by 29% QoQ
The stock's price to book (P/B) is 59% less than its 5-year quarterly average of 6.3 and 54% less than its last 4 quarters average of 5.6
The revenue has plunged by 100% YoY

Efficiency

How efficient is Avadel Pharmaceuticals business performance
The ROE has contracted by 44% from the previous quarter
The ROIC has contracted by 28% from the previous quarter
AVDL's return on assets is down by 25% since the previous quarter

Dividends

What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVDL.

Financial health

How did Avadel Pharmaceuticals financials performed over time
The total assets is 33% more than the total liabilities
AVDL's quick ratio has dropped by 88% year-on-year and by 63% since the previous quarter
Avadel Pharmaceuticals's current ratio has plunged by 86% YoY and by 60% from the previous quarter
The debt is 163% greater than the equity
Avadel Pharmaceuticals's debt to equity has soared by 150% YoY and by 42% from the previous quarter
The company's equity has shrunk by 60% YoY and by 29% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.